**Specifications Table**TableSubject areaBiologyMore specific subject areaDyslipidemia and cardiovascular riskType of dataTables and FiguresHow data was acquiredWorldwide surveyData formatAnalyzedExperimental factorsObservational, longitudinal registryExperimental featuresComparison of lipid lowering therapies administered in patients post acute coronary syndrome, as well as LDL-C target achievement.Data source locationInstitut für Herzinfarktforschung, Ludwigshafen, GermanyData accessibilityData are included in this article

**Value of the data**•These data have been collected under real life conditions across the world.•Stratification per country can help to facilitate a scientific dialogue for the benefit of coronary patients in these countries, but also help to compare treatment standards between geographies of the world.•The data presented can help to guide treatment decisions for novel lipid lowering agents.

1. Data {#s0005}
=======

See [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}.Fig. 1LDL-C target attainment for ACS cohort. (A) LDL-C target attainment by pre-ACS risk level (ESC/EAS guidelines); (B) Proportion of ACS patients with an LDL-C level of \<70 mg/dL at hospital admission and at 120-day follow-up (for patients with values available at both time points, N = 1071).Fig. 1Fig. 2LDL-C target value attainment by region. Target value attainment rates were calculated for the 1,071 patients with LDL-C data at both time points.Fig. 2Table 1Indicates the change in lipid-lowering therapy at admission to a hospital for the treatment of an ACS, as well as the changes applied during hospital stay, at discharge and after a 120 day follow up period.Table 1At admissionDuring hospital stayAt discharge120 days post ACS*N*LLT (%)AEDE/SLLT (%)AEDE/S% LLTAEDE/S*N*% LLTAEDE/SLipid lab during follow up (%)LDL-C\<70 mg/dl at follow up (%)Egypt*199*147 (26.1)29.720 (0.0)199 (100.0)54.020 (0.0)199 (100)53.120 (0.0)*151*148 (98.0)45.740 (0.0)23.8%5.6%France*468*277 (40.8)21.7220 (4.3)450 (96.2)48.0214 (3.0)453 (96.8)48.8614 (3.0)*326*312 (95.7)40.8115 (4.6)48.5%50.6%Germany*461*270 (41.4)18.4214 (3.0)447 (97.0)20.5919 (4.1)447 (97.0)20.9123 (5.0)*390*357 (91.5)21.8321 (5.4)27.9%19.3%Greece*200*159 (20.5)20.3112 (6.0)196 (98.0)31.289 (4.5)196 (98.0)31.1812 (6.0)*194*188 (96.9)29.8715 (7.7)44.3%22.1%Hong Kong*140*67 (52.1)13.861 (0.7)135 (96.4)16.461 (0.7)131 (93.6)17.361 (0.7)*136*132 (97.1)17.180 (0.0)56.6%48.1%India*521*404 (22.5)28.512 (0.4)519 (99.6)45.541 (0.2)510 (97.9)43.40 (0.0)*513*482 (94.0)37.010 (0.0)15.6%57.5%Ireland*57*32 (43.9)32.671 (1.8)55 (96.5)66.980 (0.0)57 (100)62.461 (1.8)*56*56 (100.0)601 (1.8)57.1%46.9%Italy*212*142 (33)26.719 (4.2)207 (97.6)57.843 (1.4)206 (97.2)56.049 (4.2)*171*168 (98.2)50.5511 (6.4)31.6%37.0%Jordan*40*24 (40)24.351 (2.5)39 (97.5)35.265 (12.5)40 (100)35.137 (17.5)*30*30 (100)37.330 (0.0)3.3%100.0%Lebanon*82*61 (25.6)24.491 (1.2)82 (100)55.981 (1.2)82 (100)45.182 (2.4)*78*76 (97.4)38.421 (1.3)28.2%27.3%Philippines*48*26 (45.8)48.270 (0.0)46 (95.8)60.220 (0.0)47 (97.9)56.740 (0.0)*21*21 (100)44.50 (0.0)19.0%50.0%Saudi Arabia*150*140 (6.7)23.7918 (12.0)150 (100)59.826 (17.3)150 (100)38.1364 (42.7)*150*150 (100)40.2755 (36.7)15.3%8.7%Singapore*126*84 (33.3)19.372 (1.6)121 (96)35.374 (3.2)122 (96.8)35.294 (3.2)*108*106 (98.1)33.893 (2.8)61.1%34.8%South Korea*308*162 (47.4)16.9111 (3.6)300 (97.4)22.5734 (11.0)306 (99.4)22.4736 (11.7)*301*296 (98.3)20.7227 (9.0)26.2%62.0%Taiwan*130*58 (55.4)14.424 (3.1)114 (87.7)18.582 (1.5)113 (86.9)17.693 (2.3)*123*97 (78.9)18.473 (2.4)33.3%36.6%Thailand*320*188 (41.3)16.96 (1.9)317 (99.1)27.926 (1.9)311 (97.2)28.077 (2.2)*285*275 (96.5)28.211 (3.9)51.9%25.7%UAE*200*129 (35.5)23.511 (0.5)199 (99.5)40.435 (2.5)197 (98.5)40.14 (2.0)*166*161 (97.0)39.281 (0.6)17.5%44.8%Vietnam*205*151 (26.3)17.41 (0.5)204 (99.5)21.840 (0.0)200 (97.6)19.930 (0.0)*191*186 (97.4)18.491 (0.5)13.6%26.9%All*3867*2521 (34.8)22.36104 (2.7)3780 (97.8)37.43130 (3.4)3767 (97.4)35.88187 (4.8)*3390*3241 (95.6)32.41165 (4.9)31.6%37.0%[^1]Table 2Predictors of LDL-C target value attainment among treated ACS patients.Table 2Full modelStepwise modelOR95% CIP valueOR95% CIP valueAge ≥701.200.96--1.500.109------Female0.600.47--0.77\<0.0010.610.48--0.78\<0.001BMI \>30 kg/m^2^0.630.49--0.81\<0.0010.610.48--0.78\<0.001Current smoking0.590.44--0.77\<0.0010.570.43--0.74\<0.001Sedentary lifestyle0.900.73--1.100.293------Stable angina0.880.65--1.200.418------Chronic kidney disease1.521.09--2.130.0141.581.14--2.200.006Type 2 diabetes mellitus1.331.08--1.640.0071.311.07--1.610.009History of chronic heart failure1.380.99--1.940.0601.401.00--1.960.050Hypertension0.980.77--1.250.881------Statin dose (atorvastatin dose equivalent, mg/day)1.011.004--1.016\<0.0011.0091.004--1.0150.001[^2]Table 3Regional differences in lipid-lowering therapy.Table 3Admission (N = 3867)Follow-up (N = 3558)AsiaEuropeMiddle EastP valueAsiaEuropeMiddle EastP valueStatin monotherapy58.8%53.8%69.5%\<0.00189.8%83.1%85.4%\<0.001Non-statin monotherapy1.0%2.4%0.6%\<0.0010.4%0.7%0.2%N.S.Statin+ezetimibe1.5%4.0%3.1%\<0.0012.7%5.5%9.9%\<0.001Statin+other non-statin2.1%2.8%1.5%N.S.2.2%5.8%2.8%\<0.001Not treated36.6%37.1%25.3%\<0.0014.4%4.9%1.7%\<0.001Atorvastatin dose equivalent, mean±SD mg/day[a](#tbl3fna){ref-type="table-fn"}22±1822±1725±14\<0.00127±1835±2541±18\<0.001[^3][^4]

2. Experimental design, materials and methods {#s0010}
=============================================

DYSIS II ACS was a multicenter, longitudinal, observational study that included 3867 patients from 18 countries in Europe, the Middle East, South-, Southeast- and East-Asia.

The study was approved by the relevant ethics committees and carried out in agreement with local laws.

Inclusion criteria were as follows: 1) provision of written informed consent, 2) aged ≥18, 3) hospitalized for an ACS in 2013--2014, 4) availability of a full fasting or non fasting lipid profile based on blood drawn within 24 hours of admission, and 5) not participating in a clinical trial. Data were assessed at presentation for an acute coronary syndrome (ACS), at hospital stay and discharge, as well as after a predefined period of 120 days.

The ESC/EAS dyslipidemia guidelines (2011) were used as a reference in order to determine target value attainment after 120 days [@bib1]. Low density lipoprotein (LDL-C) treatment target thus was \<70 mg/dl. Since the guidelines also highlight the use of statins in highest tolerated dose, followed by the use of lipid lowering combination therapy, we determined statin dose administered, calculated as atorvastatin equivalent doses [@bib2].

Data were collected in an electronic case report form and processed in a central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany. It was used for both collection and storage of the data.

SAS version 9.3 (Cary, NC, USA) was used for performing the calculations. Data are presented as absolute numbers and percentages (*n*/*N*), pertaining to either the baseline sample or the 3,390 patients who presented for the follow up visit.

Transparency document. Supplementary material {#s0020}
=============================================

Supplementary material.

The work was funded by Merck & Co., Inc., Kenilworth, NJ, USA. The authors of the present study would like to thank all DYSIS II ACS investigators for their contribution to the successful completion of this study.

Transparency data associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2017.11.034>.

[^1]: LLT, Lipid lowering treatment; AED, Atorvastatin equivalent dose; E/S, ezetimibe in combination with any statin: ACS, acute coronary syndrome; LDL-C, low density lipoprotein cholesterol; UAE, United Arab Emirates. % target value attainment after 120 days follow up given for those patients with recent lab values available.

[^2]: BMI, body mass index; CI, confidence interval; OR, odds ratio.

[^3]: SD, standard deviation; N.S., not significant.

[^4]: In statin treated patients (N = 2466 at admission; N = 3226 at follow up 120 days after the ACS).
